Colon or Rectal Cancer, Stage I-III, Financial Burden Assessment (EAQ162CD)

For a patient to be eligible for participation in this study, all of the following criteria must apply.

• Patients must have a life expectancy of >= 24 months
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-3
• Patients must have a newly diagnosed colon or rectal cancer (initial diagnosis, either a biopsy or curative surgery, whichever is most recent) within 60 days of registration and have not yet received radiation or chemotherapy
• Patients must have stage I, II, or III disease at the time of enrollment and will be treated with curative-intent; this can be defined either clinically or pathologically if they have already undergone surgery; for staging of both colon and rectal cancer, the definition of stage I-III is based on the seventh edition (2010) or an updated version of the tumor, node, metastasis (TNM) staging system
• Patients are not eligible if they are already enrolled on a treatment clinical trial at the time of registration; they can remain on the study if they subsequently enroll on a treatment clinical trial during the study time period
• Patients who choose to not receive radiation and/or chemotherapy after a curative-intent surgery are eligible to participate
• Patients with a history of previous malignancy (except non-melanoma skin or cervical in-situ cancer) treated (with either surgery, chemotherapy, and/or radiation) within the last 3 years are not eligible
• Patients must be able to complete questionnaires in English
• Patients must sign and give written informed consent in accordance with institutional and federal guidelines

To learn more, visit ClinicalTrials.Gov

Study Type

Phase: Observational

Principal Investigator(s)

Michael Humeniuk, MD

Sponsor(s)

ECOG-ACRIN Cancer Research Group